• Proven Science.

    Breakthrough Medicines.

Advances in the Fight Against Autoimmune Disease

Syntimmune is a clinical-stage biopharmaceutical company developing a range of drug candidates. Our lead molecule, SYNT001, which is advancing into multicenter US trials in pemphigus and warm autoimmune hemolytic anemia, targets the interaction between FcRn and IgG, modulating IgG levels as well as IgG-related inflammation and their roles in a wide range of autoimmune diseases.

A Bold Mission

Syntimmune’s mission is to leverage its position as the leader in the science of FcRn – the neonatal crystallizable fragment receptor – to create drugs that inhibit its functions, as FcRn plays a role in many critical disease associated pathways. Syntimmune’s products aim to provide transformative benefits to patients in a broad range of autoimmune and metabolic diseases.

The Leader in FcRn Science

Syntimmune’s founders and advisors are leading authorities in the science of FcRn, an important functional regulator of multiple endogenous proteins, specifically IgG and albumin. Our deep mechanistic understanding of the target biology of FcRn enables us to create medicines with high specificity that modulate distinct functions of FcRn, with powerful impact on a wide variety of diseases.

SYNT001

Lead drug candidate

25+ years

Proven scientific research on FcRn

$78M

Total committed capital

Leadership

Syntimmune is headed by renowned entrepreneurs and scientists.

David De Graaf, Ph.D.
Chief Executive Officer
Laurence Blumberg, M.D.
Business Founder, Director, President and Chief Operating Officer
Richard Blumberg, M.D.
Scientific Founder, Director and Chairman of the Scientific Advisory Board
Burt Adelman, M.D.
Senior Advisor, Director
Background

Latest News

Background

Ready to start the conversation?